Matching articles for "baloxavir"

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • September 16, 2024;  (Issue 1711)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • November 13, 2023;  (Issue 1689)
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza for the 2023-2024 season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2023 Nov 13;65(1689):177-82 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)

   
The Medical Letter on Drugs and Therapeutics • November 13, 2023;  (Issue 1689)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024
Med Lett Drugs Ther. 2023 Nov 13;65(1689):e1-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • October 16, 2023;  (Issue 1687)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • October 16, 2023;  (Issue 1687)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table...
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu. None of the drugs that are FDA-approved for treatment of influenza have clinically relevant antiviral activity against SARS-CoV-2.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):185-90 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e1-5 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • October 3, 2022;  (Issue 1660)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):153-7 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • January 10, 2022;  (Issue 1641)
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral...
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2022 Jan 10;64(1641):2-7 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)

   
The Medical Letter on Drugs and Therapeutics • January 10, 2022;  (Issue 1641)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
Med Lett Drugs Ther. 2022 Jan 10;64(1641):e1-5 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • October 4, 2021;  (Issue 1634)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):153-7 | Show Full IntroductionHide Full Introduction

Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza

   
The Medical Letter on Drugs and Therapeutics • January 11, 2021;  (Issue 1615)
The oral polymerase acidic endonuclease inhibitor baloxavir marboxil (Xofluza — Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved...
The oral polymerase acidic endonuclease inhibitor baloxavir marboxil (Xofluza — Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved for treatment of acute uncomplicated influenza in patients ≥12 years old in 2018.1 Two neuraminidase inhibitors are FDA-approved for prophylaxis of influenza: oseltamivir (Tamiflu, and generics) in patients ≥1 year old, and zanamivir (Relenza) in patients ≥5 years old.2 Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved for pre-exposure prophylaxis of influenza during institutional or community outbreaks.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):2-3 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza for 2020-2021

   
The Medical Letter on Drugs and Therapeutics • November 2, 2020;  (Issue 1610)
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table...
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):169-73 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza (online only)

   
The Medical Letter on Drugs and Therapeutics • November 2, 2020;  (Issue 1610)
...
View the Comparison Chart: Antiviral Drugs for Influenza
Med Lett Drugs Ther. 2020 Nov 2;62(1610):e176-80 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2020-2021

   
The Medical Letter on Drugs and Therapeutics • September 21, 2020;  (Issue 1607)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Tables 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):145-50 | Show Full IntroductionHide Full Introduction